S89021 |
Pibrentasvir |
| 源叶(MedMol) | 98% |
- 产品描述： Pibrentasvir (ABT-530) 是一种新型的泛基因型丙型肝炎病毒 hepatitis C virus (HCV) NS5A 抑制剂，其针对包含基因型1至6的NS5A的HCV复制子的EC50值为1.4 pM至5.0 pM
- 靶点： GT5a(Cell-free assay):1.4 pM(EC50); GT1a H77(Cell-free assay):1.8 pM(EC50); GT2b(Cell-free assay):1.9 pM(EC50); GT4a(Cell-free assay):1.9 pM(EC50); GT3a(Cell-free assay):2.1 pM(EC50);GT2ab(Cell-free assay):2.3 pM;GT6a(Cell-free assay):2.8 pM;GT1b Con1(Cell-free assay):4.3 pM;GT2a JFH-1(Cell-free assay):5.0 pM
- 细胞实验： Cell lines: Huh-7 human hepatoma cell line, CEM-SS cells Concentrations: -- Incubation Time: 6 days Method: Antiviral activity assays for HIV-1 and HBV are performed at Southern Research Institute. Pibrentasvir is tested in an HIV-1 antiviral cytoprotection assay using CEM-SS cells and the IIIB strain of HIV-1. Briefly, virus and cells are mixed in the presence of pibrentasvir or zidovudine (AZT; positive control) and incubated for 6 days. The titers of the virus are determined beforehand such that the virus-infected control wells exhibited approximately 85% to 95% loss of cell viability due to virus replication. Therefore, antiviral effect or cytoprotection is observed when a compound prevented virus replication. Six days after infection, 20 to 25 μl of MTS reagent is added per well, and the microtiter plates are then incubated for 4 to 6 h to assess cell viability. Plates are read spectrophotometrically at 490/650 nm with a Molecular Devices Vmax or SpectraMax Plus plate reader.
- 参考文献：
1. Teresa I Ng, et al. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02558-16.
- 溶解性： Soluble in DMSO、Ethanol
- 保存条件： -20°C
- 配置溶液浓度参考：
1mg 5mg 10mg 1 mM 0.898 ml 4.492 ml 8.983 ml 5 mM 0.18 ml 0.898 ml 1.797 ml 10 mM 0.09 ml 0.449 ml 0.898 ml 50 mM 0.018 ml 0.09 ml 0.18 ml
- 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。
输入产品批号：
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)
